PHARMAESSENTIA CORP.
Area: Government, Academia and Research Institutes
Booth No: M534
Website: https://hq.pharmaessentia.com/tw
Exhibitor Profile
PharmaEssentia's novel product, Ropeginterferon alfa-2b, is granted the marketing authorization for the treatment of Polycythemia Vera (PV) by EMA, Taiwan, Korea, US, Japan, Singapore, Malaysia, China, Brazil, Argentina and Hong Kong. Additionally, Ropeginterferon alfa-2b for the treatment of Essential Thrombocythemia (ET) is also approved by Taiwan TFDA in May, 2026.
Brands
Ropeginterferon alfa-2b
Exhibit Products
Exhibitors you may be interested in
Highest Rated